Corporate | 7 October 2003 08:53

Eckert & Ziegler AG english

NEMOD Biotherapeutics: successful biodistribution studies for KaroMab (TM) Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– NEMOD Biotherapeutics: successful completion of biodistribution studies for KaroMab(TM) Berlin, 07.10.2003. NEMOD Biotherapeutics GmbH & Co KG, a biopharmacutical company focusing on oncological indications, announced successful completion of preclinical biodistribution studies for the systemic delivery of the company’s proprietary product KaroMab(TM). The monoclonal antibody that targets the Thomsen-Friedenreich antigen solely found in tumors accumulates strongly and specifically in colon and breast carcinomas implanted in mice. “With this preclinical study we have been able to obtain a second antibody candidate for clinical development besides our lead product PankoMab(TM)”, said Dr. Andreas Hey, COO of NEMOD Biotherapeutics GmbH & Co. KG. “Together with a highly specific antibody against Lewis Y in preclinical development we now have a strong tumor antibody portfolio for outlicensing to strategic partners.” In this biodistribution study different antibody formats of KaroMab(TM) were radiolabelled with 111-Indium and injected in mice xenografted with colon and breast tumor implants. The measurement of 111-Indium uptake in several organs and the tumor revealed that about 10% of the injected dose per gram accumulated in the tumor. The remainder of the antibody rapidly cleared off the circulation, associated with a renal load as expected decreasing with the size of the antibody format. NEMOD Biotherapeutics GmbH & Co. KG (www.nemod.com) is a drug discovery company affiliated with publicly listed Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 00056597000, German Prime Standard). NEMOD’s development program focuses on oncological indications like gastric, colon, liver, and breast cancer. Thomsen-Friedenreich (abbreviated “TF”) is an antigen unique in its specificity as it does solely express on tumor cells. TF can be be found on a variety of solid carcinomas including colon, gastric, pancreatic, lung, breast and ovarian cancer. Enquiries: NEMOD Biotherapeutics GmbH & Co. KG Dr. Andreas Hey, Chief Operating Officer Tel: +49 (0)30 9410 84-282 Email:andreas.hey@nemod.com http://www.nemod.com end of message, (c)DGAP 07.10.2003 ——————————————————————————– WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 070853 Okt 03